Andrew Adams

Dr. Andrew Adams is the Group Vice President of Molecule Discovery and Director of Genetic Medicines at Eli Lilly and Company. He leads the discovery of new therapies in Neuroscience, focusing on core areas such as pain and neurodegeneration. Dr. Adams also oversees the growth of Lilly’s genetic medicines portfolio, which includes RNA, gene therapy, and gene editing. He earned a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Before joining Lilly in 2011, he was a postdoctoral fellow at Harvard Medical School. During his tenure at Lilly, he has held various roles in discovery, external innovation, and led early trailblazer teams.